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Abstract
Objective: Negative pressure wound therapy (NPWT) has been used to treat diabetic 
foot ulcerations (DFUs). Its action on the molecular level, however, is only partially 
understood. Some earlier data suggested NPWT may be mediated through modification 
of local gene expression. As methylation is a key epigenetic regulatory mechanism of 
gene expression, we assessed the effect of NPWT on its profile in patients with type 2 
diabetes (T2DM) and neuropathic non-infected DFUs.
Methods: Of 36 included patients, 23 were assigned to NPWT and 13 to standard therapy. 
Due to ethical concerns, the assignment was non-randomized and based on wound 
characteristics. Tissue samples were obtained before and 8 ± 1 days after therapy 
initiation. DNA methylation patterns were checked by Illumina Methylation EPIC kit.
Results: In terms of clinical characteristics, the groups presented typical features of 
T2DM; however, the NPWT group had significantly greater wound area: 16.8 cm2 vs  
1.4 cm2 (P = 0.0003). Initially only one region at chromosome 5 was differentially 
methylated. After treatment, 57 differentially methylated genes were found, mainly 
located on chromosomes 6 (chr6p21) and 20 (chr20p13); they were associated with 
DNA repair and autocrine signaling via retinoic acid receptor. We performed differential 
analyses pre treatment and post treatment. The analysis revealed 426 differentially 
methylated regions in the NPWT group, but none in the control group. The enrichment 
analysis showed 11 processes significantly associated with NPWT, of which 4 were linked 
with complement system activation. All but one were hypermethylated after NPWT.
Conclusion: The NPWT effect on DFUs may be mediated through epigenetic changes 
resulting in the inhibition of complement system activation.
Introduction
Diabetic foot syndrome (DFS) is characterized as an 
infection, ulceration, or destruction of deep tissues of the 
foot associated with neuropathy and/or peripheral arterial 
disease (1). Diabetic foot ulcer (DFU) is a frequently 
diagnosed form of DFS. The yearly incidence rate reported 
among patients with diabetes has reached 6.0% (2). It is 
associated with a high rate of recurrence, amputation, 
and mortality (3). The standard management of the DFU 
includes glycemic control, offloading, revascularization, 
antibiotics, surgical debridement and different topical 
dressings. Despite the new treatment modalities for DFUs, 
many patients still suffer from prolonged treatment courses 
and concomitant complications. There is subsequently a 
significant demand for adjunct therapies to improve the 
prognosis of these patients. Among supportive strategies, 
negative pressure wound therapy (NPWT) is emerging as 
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an area of a great clinical interest and research. It has found 
its application in many clinical situations, including DFU 
management (4, 5). NPWT is based on the use of occlusive 
dressings applied to the wound with subatmospheric 
pressure gradients, typically −75 mmHg to −125 mmHg, 
usually continuous, transmitted through drains from 
a vacuum generator. NPWT causes tissue deformations 
facilitating wound borders closure. It stimulates a wound 
healing cascade that includes exudate removal, reduction 
of edema, neoangiogenesis, and granulation promotion 
(reviewed in (6)). Its mechanism of action on the 
molecular level, however, is only partially understood. 
NPWT results in a local tissue alteration toward more pro-
angiogenic and anti-inflammatory molecular conditions. 
Specifically, growth factors, inflammatory cytokines, and 
matrix metalloproteinases constitute molecular pathways 
affected by this therapy (reviewed in (6)). Previous animal 
and human data suggested that it might act through 
modification of local gene expression (7, 8); however, most 
of them focused on particular molecular pathways and 
the analysis was performed by Q-PCR methods. Recently, 
we conducted an analysis in which we characterized 
transcriptome wide gene expression profile using Illumina 
microarrays in patients with type 2 diabetes (T2DM) and 
DFU in comparison with standard therapy (9). In light 
of this prior evidence of differential expression of several 
genes between the two treatment methods (9), it seemed 
strongly justified to test whether these can also be seen at 
the epigenetic level of gene methylation, a key regulatory 
mechanism of gene expression.
In this study, we performed a genome-wide DNA 
analysis to compare the effect of NPWT versus standard 
therapy on the methylation profile in the wound bed of 
patients with type 2 diabetes (T2DM) and neuropathic, 
non-infected DFUs.
Methods
Patients
Thirty-six consecutive patients with T2DM and DFUs 
from an outpatient clinic of the Department of Metabolic 
Diseases, University Hospital, Krakow, a tertiary academic 
outpatient center for patients with DFS in southern 
Poland, were selected using previously described criteria 
(9). Patients were qualified to the study if they had 
peripheral diabetic polyneuropathy (diagnosed with 
at least two standard clinical tests) complicated by 
superficial neuropathic foot ulcerations. We included 
patients with the presence of no more than three 
neuropathic, non-infected, non-ischemic ipsilateral foot 
wounds. Specific inclusion criteria comprised (a) a clinical 
diagnosis of T2DM and (b) the presence of no more than 
three neuropathic, clinically non-infected foot wounds. 
Exclusion criteria included (a) clinically significant 
ischemia defined by the lack of pulses of both main 
pedal arteries and/or an ankle-brachial index less than 
0.9, (b) symptoms of infection, (c) bilateral ulcerations, 
(d) active osteomyelitis, and (e) active Charcot foot 
(based on clinical examination and X-ray imaging). The 
patients were assigned either to standard therapy alone 
(n = 13) or standard combined with NPWT (n = 23). The 
assignment to NWPT was non-random and based on 
wound characteristics, mainly area (>1.0 cm2). This was 
done to mirror the current use of NPWT in patients 
with larger foot wounds in routine clinical practice (10, 
11, 12). Patients with smaller ulcerations (≤1.0 cm2) 
were assigned to the comparator group. However, in the 
presence of technical difficulties for NPWT application 
(e.g. unfavorable localization for placement) or lack of 
patient consent for NPWT, patients were allocated to the 
comparator group as well. A commercial NPWT system 
(Renasys EZ Plus, Smith & Nephew, London, UK) was 
used and continuous negative pressure of −120 mmHg 
was applied to the ulceration filled with comprehensive 
Renasys NPWT foam dressing. Tissue samples from the 
wound bed and blood were obtained at study onset and 
after 8 days of treatment; however, a deviation of 1 day 
more or less was exceptionally allowed. Clinical data were 
collected at the baseline visit. This study was approved 
by the Jagiellonian University Bioethics Committee in 
accordance with the Declaration of Helsinki. Written 
informed consent was obtained from patients prior 
to inclusion.
Gene methylation arrays
DNA was isolated from samples obtained at two time 
points (pre- and post-treatment). Bisulfite conversion 
was performed using 500 ng of DNA with EZ DNA 
Methylation-Direct Kit (Zymo, Irvine, CA, USA). The next 
steps were performed according to the Illumina protocol 
of Methylation EPIC kit (Illumina, San Diego, CA, USA). 
Bisulfite-converted-DNA was amplified (whole-genome 
amplification), fragmented, and precipitated. After 
resuspension, DNA was hybridized onto Bead Chips for 
24 h at 37°C. The non-hybridized and nonspecifically 
hybridized DNA was washed away following extension 
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and staining. Imaging was performed using HiScan 
(Illumina, USA).
Bioinformatics and statistical analysis
For analysis of the characteristics of the study groups, 
we used Statistica Software v. 12.0 (StatSoft, Tulsa, OK, 
USA). The Shapiro–Wilk test was performed to check 
normality. Differences between groups were assessed 
by the t-test or U test for normally and non-normally 
distributed continuous variables, respectively, and by 
chi-square or Fischer’s exact test for categorical variables. 
Continuous variables are presented as mean ± s.d. or 
median (interquartile range).
Quality control of the samples was performed using 
bioconductor package ‘minfi’ in statistical software 
R (version 3.5.0), according to ‘The minfi User’s Guide’. 
Using the ‘minfi’ package a Subset-quantile Within Array 
Normalization (SWAN) procedure was applied to the 
raw data.
Target statistical analysis was performed using 
package ‘ChAMP’ in statistical software R version 3.5.0. 
In total, 72 samples (half pre-treatment and another half 
post-treatment) and 846,232 features were analyzed. 
Four different comparisons were performed: (1 and 2) 
difference between pre- and post-treatment in control 
arm as well as NPWT arm; (3 and 4) difference between 
control and NPWT arms pre-treatment as well as or post-
treatment. Prior to the endpoint analysis, confounding 
effects associated with batch (methylation array) and 
gender were removed. Differentially methylated regions 
were detected using the ‘ProbeLasso’ algorithm (13) with 
FDR 0.05. Gene set enrichment analysis was performed 
using Fisher’s exact test with FDR 0.05. The SEPIRA 
package was used as implemented in R Bioconductor. The 
cell counts were estimated as proposed by the authors of 
EpiDISH and FlowSorted.Blood.EPIC packages (14).
Results
The clinical characteristics of the study groups are shown 
in Table 1; of note, borderline differences occurred for 
BMI and HbA1c level. The NPWT group was, however, 
characterized by much greater wound area: 16.8 (IQR: 
6.2–20.2) vs 1.4 (IQR: 1.0–2.2) cm2 (P = 0.0003), in line 
with patients’ original treatment allocation.
First, we checked whether samples from the two 
cohorts differed in methylation status before treatment. 
Only one region was differentially methylated between 
these samples at chromosome 5 (5:140753380–
140753692). This site encodes the protocadherin gamma 
subfamily, PCDHGA4, a cell adhesion protein (dependent 
on calcium) which is involved in the maintenance of 
specific neuronal connections in the brain (15).
Next, we looked into the effects of NPWT and 
standard therapy after treatment. Fifty-seven differentially 
methylated genes were found. After being subjected 
to enrichment analysis, they were mainly located on 
chromosomes 6 (chr6p21) and 20 (chr20p13). These areas 
are associated with DNA repair and autocrine signaling 
via retinoic acid receptor (Table 2).
Subsequently, we performed a differential analysis 
of the two time points – pre- and post-treatment. The 
analysis revealed 426 differentially methylated regions in 
the NPWT group (presented in Supplementary Table 1, 
see section on supplementary data given at the end 
of this article). A heatmap with regions characterized 
by the largest differential methylation in the NPWT 
Table 1 Baseline characteristics of the study groups.
NPWT Standard therapy P value
Participants, n 23 13 N/A
Male, n 19 10 0.70
Age, years 68.3 ± 8.5 64.9 ± 7.1 0.23
BMI, kg/m2 26.3 (24.7–29.7) 29.2 (27.1–32.7) 0.06
Diabetes duration, years 14.1 ± 1.5 17.0 ± 2.1 0.27
HbA1c, % 6.8 (6.0–7.6) 7.6 (7.1–8.1) 0.08
HbA1c, mmol/mol 50.8 (42.1–59.6) 59.6 (54.1–65.0) 0.08
eGFR, mL/min/1.73 m2 (CKD EPI) 89.0 (66.0–92.0) 72.0 (52.0–87.0) 0.25
Insulin therapy, n 20 12 1.00
Smoking current/former/never, n 3/11/6 2/6/4 0.96
Wound duration, weeks 12.0 (10.1–22.9) 7.1 (3.7–14.5) 0.06
Wound area, cm2 16.8 (6.2–20.2) 1.4 (1.0–2.2) 0.00
CRP, mg/L 6.08 (0.95–26.13) 6.61 (2.78–12.02) 0.81
The age and diabetes duration, which fit into the normal distribution, are presented as mean and standard deviation. The other quantitative traits are 
presented as median and interquartile range.
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arm is shown in Fig. 1. No such regions were found in 
the control cohort. Results from the NPWT group were 
subjected to pathway enrichment analysis in order to 
find their molecular signatures. It showed 11 processes 
that were statistically significantly associated with NPWT 
(Table 3). To test whether the results of differential 
methylation might be driven by a degree of glycemic 
control in the study subjects, we performed an additional 
analysis. Due to limited sample size, it was unfeasible 
to introduce an interaction term in the linear model. 
Therefore, to detect an association of CpG sites with 
HbA1c levels, we performed an analysis of the relationship 
between patients’ HbA1c and the difference in methylation 
(matched samples) between pre and post treatment. This 
analysis showed no sites under the FDR <0.05.
Four out of 11 identified processes were associated 
with complement system activation. Among several genes 
related to complement system most, apart from one – CLU 
- which is an inhibitor of complement system activation, 
were hypermethylated after NPWT leading to inhibition 
of complement system activation (Table 4).
In order to better understand the mechanism of NPWT 
action, we performed an analysis of cellular subpopulations 
on the methylation data of our patients’ tissue samples 
from the wound bed. These samples constituted a cellular 
mixture, and the analysis was based on molecular markers 
specific for cellular populations (16). The results of our 
analysis suggested that NPWT seemed to unload the wound 
from epithelial cells and fibroblasts, as the number of 
these cell types decreased more in the treatment arm than 
in the control arm. Moreover, NPWT led to a decline in 
most of the inflammatory cells, suggesting that prolonged 
inflammation was being reduced (Supplementary Table 2). 
Neutrophils, known for their potency for phagocytosis, 
were the only subpopulation for which an increase 
was observed. Additionally, the only inflammatory cell 
subpopulation which did not decrease in the NPWT arm 
as much as in the control group was that of the monocytes. 
Given the well-established phenotypic switch from pro-
inflammatory to anti-inflammatory macrophages that 
takes place in wound healing, we searched for non-direct 
results which would support this hypothesis. To further 
refine our findings, we used the SEPIRA approach (17). 
In short, we trained a Gene Regulatory Network with 
GTEx expression data (spleen and blood for reference of 
expression in immune cells, as well as muscle and skin, 
for estimation of the target network) and then tested the 
regulatory activity of the selected transcription factors 
using the expression (9) and the methylation data. Using 
the above-described approach together with standard 
Wilcoxon’s signed-rank test, we found transcription 
factors that were differentially activated pre and post 
treatment in the NPWT arm. The results showed that 
the activation of many transcription factors responsible 
for macrophage activation had changed between the two 
time points in NPWT arm (Supplementary Table 3).
Discussion
Here, for the first time in the literature, we provide 
evidence of the molecular mechanism of NPWT in the 
Table 2 List of post treatment enriched processes.
Pathway name OR (95% CI) Adj P value
chr6p21 71.95 2.38E-38
chr20p13 31.33 0.0048
DELACROIX_RAR_BOUND_ES 9.19 0.0050
MORF_DDB1 12.8 0.0060
Difference between NPWT and control group is presented.
Figure 1
Heatmap presenting the largest differentially methylated regions (all regions contain more than 45 probes with FDR <0.05). Only samples in the NPWT 
arm are included. Samples are presented in pairs; in each pair, the first sample is pre-treatment and the second is post-treatment.
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chronic wound bed of DFUs, namely its impact on DNA 
methylation of genes in several pathways. In particular, 
we show that the clinical effect of NPWT may result from 
an inhibition of complement activation. Among the 
genes that were hypermethylated and thus inhibited after 
NPWT, we identified those that coded proteins playing a 
key role in complement system activation, such as C2, C3, 
C4A and C4B (18). This is likely to substantially affect the 
process of activating the complement system. The finding 
from this study is supported by our previous data on the 
impact of NPWT on the differential gene expression in DFU 
patients with T2DM (9). Among genes upregulated after 
NPWT, we identified C1QBP (Complement component 
1, q subcomponent binding protein), which confirms 
that the NPWT effects may result from inhibiting the 
complement system.
Wound healing is an orchestrated process in which 
several phases occur one after another. The inflammatory 
stage is followed by proliferative and remodeling phases 
(19). Poorly healing wounds, such as DFUs, do not follow 
this scheme and remain predominantly in the chronic 
inflammatory stage. Healing also hinges on the tissue 
formation phase, when cells within the wound bed become 
proliferative and migratory (19). One can hypothesize 
that the NPWT-induced complement inhibition may 
allow cells to move onto the next stages of wound healing. 
Diabetes induces chronic inflammation via prolonged 
M1 macrophage polarization whose phenotype is similar 
to ‘inflammatory macrophages’ which are seen in early 
stages of wound healing (20). Of note, the complement 
system is activated in both acute and chronic processes 
(21). The results of the study performed on db/db and 
control mice has shown that complement activation 
(checked by C5a concentration) was three times higher in 
diabetic animals than in healthy controls (22). A similar 
effect has been observed for C3 fragments (C3a, C3b, 
iC3b) (22). Furthermore, the utilization of the classical 
complement pathway inhibitor, PIC1, led not only to 
a decrease of complement activation by 25%, but also 
reduced a number of infiltrating neutrophils. It was also 
shown that complement activation differed between 
non-diabetic Zucker lean controls and Zucker Diabetic 
fatty rats following cardiac ischemia and reperfusion 
and was also higher in the latter group, accompanied 
by both larger infarct size and neutrophil accumulation 
(23). In the same model, use of complement inhibitor 
FUT-175 led to a decrease of complement activation 
and neutrophil-mediated myocardial cell death (23). 
Finally, another study performed on C3-deficient mice 
showed faster progression of wound healing compared 
to mice with a normally activated complement system 
(24). The authors also showed that reconstitution of 
C3−/− mice with serum from C+/+ mice abrogated the 
healing, which suggests that activation of a complement 
system might have a negative effect on the progression 
of wound healing. Similar results were obtained for the 
Table 3 List of enriched processes for NPWT group (post-treatment vs pre-treatment).
Pathway name OR (95% CI) Adj P value
chr6p21 27.25 4.94E-76
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION 9.04 0.0023
REACTOME_INITIAL_TRIGGERING_OF_COMPLEMENT 39.70 0.0024
MODULE_130 22.47 0.0024
KEGG_TYPE_I_DIABETES_MELLITUS 13.14 0.0052
MOREAUX_MULTIPLE_MYELOMA_BY_TACI_UP 3.54 0.0052
FEVR_CTNNB1_TARGETS_UP 2.84 0.0058
BRIDEAU_IMPRINTED_GENES 9.29 0.0065
BIOCARTA_COMP_PATHWAY 22.68 0.0068
LEI_MYB_TARGETS 3.79 0.0068
MIKKELSEN_ES_ICP_WITH_H3K4ME3 2.81 0.0068
Table 4 Results of methylation levels of genes involved in the complement system pathway at two times points (pre-treatment 
and post-treatment) in the NPWT group.
Chromosome Start-end dmrP Gene symbol betaAv_A betaAv_C
1 159680459-159684534 5.19E-15 CRP 0.791 0.836
19 6712307-6714211 9.07E-18 C3 0.788 0.827
6 31911212-31915360 1.87E-12 C2, CFB 0.662 0.700
6 31963441-31964765 2.12E-17 C4B, C4A 0.742 0.782
8 27468411-27470257 1.61E-9 CLU 0.336 0.303
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C5 complement element. The inhibition of complement 
also led to increased vascularization of the wounds, 
enabling cells to move to the next stage of the healing 
process. These results have led to a generation of several 
complement inhibitors, although few have been applied 
to clinical practice, with the majority undergoing 
development in the pre-clinical phases of trials (25). Of 
note, the recent study focusing on the safety of long-term 
C3 inhibitor compstatin (Cp40 analog) use in the animal 
model of non-human primates showed that it accelerated 
wound healing with no weakening of immune system 
or increased susceptibility to infections compared to the 
control group (26). Since chronic DFUs may heal better 
with NPWT, which according to our experiments, may 
be mediated through complement inhibition, these 
inhibitors might also prove to be valuable options for 
DFU treatment. Interestingly, earlier reports described 
that larval debridement therapy (also known as maggot 
therapy) might act, among other mechanisms, through 
the inhibition of the complement system (27). Maggot 
therapy currently belongs, as does NPTW, to a group of 
supportive therapies in DFU that are sometimes used to 
accelerate wound healing.
We also looked into possible cellular subpopulation 
changes which take place during the NPWT therapy. We 
observed a removal of most of the inflammatory cells from 
the wound bed. Only the number of neutrophils increased. 
Neutrophils are believed to be responsible for complement 
activation and creation of pro-inflammatory feed-forward 
loop. At the same time, however, it is known that apart from 
their effects on the oxidative burst, they play an important 
role in fine-tuning the inflammatory response as they can 
express and produce anti-inflammatory cytokines (IL-1a, 
TGF-B), colony-stimulating factors (G-CSF, GM-CSF) and 
immunomodulatory cytokines (28). It was also shown 
that defensin human neutrophil peptide-1 (HNP-1) is able 
to inhibit activation of the classical complement pathway 
by inhibition of C1q hemolytic activity (29). The effect 
of complement inhibition by neutrophils has also been 
reported. Moreover, since it is known that diabetes itself 
induces uncontrolled complement system activation, 
which might lead to vascular events, neuropathy, 
retinopathy and DFS (30, 31, 32), the NPWT therapy 
might have a more pronounced effect in diabetic patients 
and differently influence the cellular composition of the 
wound. Moreover, the only inflammatory cells that did not 
decease in the NPWT arm as much as in the control group 
were the monocytes. Possible explanation for the results 
observed in our research is that monocytes residing in 
the wound are being transformed into anti-inflammatory 
macrophages (M2) and advance the healing process in 
NPWT more than in the control arm. It was shown that 
neutrophils have the ability to polarize the monocytes to 
M2 macrophages (33). Our analysis of the methylation 
state of transcription factors seemed to support this 
hypothesis as it showed a number of transcription 
factors earlier proven to be associated with macrophage 
polarization as well as wound healing. IRF6 was shown 
to be crucial for macrophage activation (34), enforced 
expression of Hoxa3 was shown to promote resolution 
of the inflammation and wound healing in diabetic mice 
by inhibition of proinflammatory gene expression and 
induction of anti-inflammatory phenotype (35). A similar 
effect was seen for NR1D1 (36). Expression of GATA3 
had no effect on M1 macrophage markers, but enhanced 
the M2 phenotype (37). Apart from transcription factors 
responsible for macrophage polarization, our analysis 
showed some other transcription factors involved in 
the wound healing process. For example, Nrf2 was 
shown to protect the cells from oxidative stress during 
wound healing (38). Additionally, zinc finger proteins 
activate Notch1, which is responsible for mesenchymal 
cell differentiation (39). TRIP6 is known to influence 
acquisition of locomotor phenotype, its knockdown leads 
to increased cell motility and might (40). Also, TEAD has 
been shown to stimulate cell proliferation and migration 
(41). SOX10 also influences EMT and motility (42). 
However, it should be emphasized that the hypothesis 
described earlier is currently not supported by any direct 
experimental evidence based on reference cell sorting 
technique. We are only able to provide the results of 
in silico analysis.
Our results showing NPWT’s modification of the 
wound-healing cascade are in line with a murine model 
study on epigenetic changes in bone marrow progenitor 
cells that influence the inflammatory phenotype and 
alter wound healing in T2DM (43). So far, only a few 
studies on methylation changes have been conducted 
on DFUs in humans; however, none of them examined 
whole-genome methylation changes after NPWT. One 
study utilizing genome-wide DNA methylation within 
the context of DFUs was performed involving patient-
derived fibroblasts. In this study, an epigenetic pattern of 
metabolic memory in these cells was proven and elicited 
targets for the functioning of wound healing (44).
The study has several limitations and shortcomings. 
First, we used a non-random study design, which may 
have predisposed this research to biases by a number 
of confounding factors, such as potential differences in 
baseline characteristics (e.g. wound size). Risk of such 
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biases in our study should be considered significant, as is 
usually the case in non-randomized clinical experiments. 
We decided not to use randomization in patients with 
larger ulcers due to ethical reasons. DFU is a dangerous, 
potentially disabling and life-threatening complication, 
and NPWT has well-documented benefits in these 
patients (reviewed in (9)). We assigned patients to groups 
according to local and international research and clinical 
practice as well as available guidelines concerning on 
NPWT use in DFU (10, 11, 12, 45, 46). It is of note, 
however, that initially the samples from the two cohorts 
differed in methylation status before treatment only 
in one chromosomal region, while many more such 
differences were detected after treatment. Nevertheless, 
we cannot exclude that even this single chromosomal 
region difference may have resulted in a selection bias. 
The potential impact of hypoglycemic therapies used in 
our study groups could have also potentially influenced 
our results. However, it should be noted that almost all 
patients in this study were on insulin at the onset of study 
entry. It is thus unlikely that hypoglycemic therapy had 
an effect on the study results; however, we cannot exclude 
the possible effect of other known and unknown factors. 
Thirdly, the number of samples was rather limited, which 
influenced the power of the analysis. Thus, some regions 
characterized by smaller methylation differences could 
have remained undetected. Additionally, the results of this 
study should be considered in the context of the duration 
of NPWT use. Longer, as well as shorter experiments, 
might have provided different results as other molecular 
mechanisms could exert an effect on healing. The length 
of NPWT use varies across institutions from a few days to 
several months (reviewed in (9)); the 8-day duration used 
in this study reflects our routine clinical practice (12). Of 
note, in a similar study, NPWT was shown to exert local 
molecular effects after 7 days of treatment (47). Finally, 
no other experimental method was used to confirm these 
findings, including functional experiments or validation 
in independent cohorts.
Conclusions
In summary, we found initial evidence that the effect 
of NPWT on DFUs may be mediated through epigenetic 
alterations, resulting mainly in the inhibition of 
complement system activation. This discovery holds 
potential clinical implications and may be of value in 
guiding the development of new therapies for DFUs.
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